-
Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia | Markets Insider
Source: Buzz FX / 23 Apr 2024 00:56:19 America/Chicago
Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia RTTNewsApr. 23, 2024, 01:18 AM (RTTNews) - Sanofi - Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twic
Read more...